Sarepta Therapeutics, Inc. (SRPT)
| Market Cap | 14.58B |
| Revenue (ttm) | 1.40B |
| Net Income (ttm) | 16.90M |
| Shares Out | 94.52M |
| EPS (ttm) | 0.40 |
| PE Ratio | 385.50 |
| Forward PE | 29.19 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,307,416 |
| Open | 156.46 |
| Previous Close | 156.75 |
| Day's Range | 153.65 - 156.70 |
| 52-Week Range | 55.25 - 173.25 |
| Beta | 0.95 |
| Analysts | Buy |
| Price Target | 187.00 (+21.27%) |
| Earnings Date | Jul 31, 2024 |
About SRPT
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping... [Read more]
Financial Performance
In 2023, SRPT's revenue was $1.24 billion, an increase of 33.26% compared to the previous year's $933.01 million. Losses were -$535.98 million, -23.81% less than in 2022.
Financial StatementsAnalyst Forecast
According to 18 analysts, the average rating for SRPT stock is "Buy." The 12-month stock price forecast is $187.0, which is an increase of 21.27% from the latest price.
News
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on June 28, 2024 that were previously app...
Will Elevidys Approval Make Sarepta Stock An Acquisition Target?
The stock price of Sarepta Therapeutics, a biotech company focused on the discovery and development of RNA-targeted therapeutics and gene therapy for the treatment of rare diseases, was up 30% on Frid...
Sarepta CEO on what's next after expanded muscular dystrophy drug approval
Douglas Ingram, Sarepta CEO, joins 'Fast Money' to talk FDA approval of Elevidys and its impact on the company's stock.
TD Cowen's Ritu Bara talks Sarepta stock skyrocketing on FDA gene therapy approval
Ritu Baral, TD Cowen Sr. Biotechnology Analyst, joins 'Closing Bell Overtime' to talk Sarepta's approval from the FDA for its Duchenne gene therapy and how it drove the stock to its best trading day i...
Sarepta's Expanded Approval Unlikely To Influence Novo Holdings' Acquisition of Catalent, But Provides Investor Protection Amid Uncertainty
Shares of Catalent Inc CTLT, which manufactures Elevidys, are trading higher with a strong session volume of 3.6 million compared to an average volume of 1.6 million.
Wall Street Beats to Host Conference Call with Sarepta CEO on Ground-Breaking Expanded Label Approval
SAN DIEGO--(BUSINESS WIRE)--Wall Street Beats is pleased to announce an investor conference call with Doug Ingram, CEO of Sarepta Therapeutics, following the landmark FDA approval expanding the label ...
Sarepta's Expanded FDA Approval For Elevidys Potentially Shaping Future FDA Reviews, Analyst Says
On Thursday, the FDA approved the labeled indication for Sarepta Therapeutics Inc's SRPT Elevidys (delandistrogene moxeparvovec-rokl) to include individuals with Duchenne muscular dystrophy (DMD) who ...
Sarepta (SRPT) Soars on FDA Approval on Muscular Dystrophy Treatment
Sarepta (SRPT) soars after the FDA approves expanded use of their Muscular Dystrophy treatment. Jenny Horne weighs in on this story.
Sarepta Soars on Expanded Approval for Muscular Dystrophy Drug
Sarepta Therapeutics' gene therapy received expanded US approval to include more children with a deadly muscle disease. The treatment's approval was widened for use in patients who are at least 4 year...
Sarepta Therapeutics Soars on Expanded Approval for Its Muscular Dystrophy Drug
Sarepta Therapeutics (SRPT) shares soared in premarket trading Friday, a day after the Food and Drug Administration (FDA) allowed expanded use of the biotech's treatment for a rare muscle disease in c...
Sarepta Therapeutics' stock soars 38% after FDA expands use of its Duchenne muscular-dystrophy drug
Sarepeta Therapeutics Inc.'s stock soared 38% in premarket trade Friday, after the biotech said the U.S. regulator has approved an expanded indication of its treatment for the rare muscle disorder Duc...
Sarepta Stock Surges on Expanded Approval for Elevidys. What Wall Street Thinks.
The biopharmaceutical company says the drug was approved for ambulatory and non-ambulatory people, who are at least 4 years old, and with a confirmed mutation in the DMD gene.
FDA Approves Expanded Use For Sarepta's Rare Muscular Dystrophy Gene Therapy
Thursday, the FDA approved labeled indication for Sarepta Therapeutics Inc's SRPT Elevidys (delandistrogene moxeparvovec-rokl) to include individuals with Duchenne muscular dystrophy (DMD) with a conf...
Sarepta surges as investors cheer expanded use of gene therapy
Sarepta Therapeutics shares surged about 36% in premarket trading on Friday as an expanded use approval opened up a bigger market in the U.S. for its gene therapy for patients with Duchenne muscular d...
Why has the Sarepta stock price (SRPT) gone up more than 35%?
Sarepta Therapeutics (NASDAQ: SRPT), a pharmaceutical company that describes itself as specializing in “precision genetic medicine for rare diseases”, saw its stock price shoot up by 36% in after-hour...
Sarepta Therapeutics receives expanded approval for Elevidys
Sarepta Therapeutics Inc (NASDAQ: SRPT) rallied a whopping 40% in extended hours today following a key announcement from the U.S. Food and Drug Administration regarding Elevidys. Elevidys is the comp...
US FDA approves expanded use of Sarepta's Duchenne gene therapy
The U.S. Food and Drug Administration allowed the expanded use of Sarepta Therapeutics' gene therapy for all patients with Duchenne muscular dystrophy aged four and above on Thursday.
Sarepta Therapeutics Announces Expanded US FDA Approval of ELEVIDYS to Duchenne Muscular Dystrophy Patients Ages 4 and Above
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics announces the expanded U.S. FDA approval of ELEVIDYS to Duchenne muscular dystrophy patients ages 4 and above.
Pfizer's gene-therapy trial failure boosts Sarepta's stock
Shares of Sarepta Therapeutics Inc. SRPT, -1.15% gained 4% premarket on Thursday after a potential competitor to its gene therapy stumbled in a late-stage trial.
Sarepta Therapeutics stock to enter S&P MidCap 400: Should you buy?
Sarepta Therapeutics (NASDAQ:SRPT) is set to make a significant move by entering the S&P MidCap 400 index, replacing Shockwave Medical. This change, effective before trading begins on June 3, 2024, fo...
Gene Therapy Pioneer Jerry R. Mendell, M.D.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that TIME named renown neuromuscular researcher...
Sarepta Therapeutics Announces First Quarter 2024 Financial Results and Recent Corporate Developments
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the first quarter 2024. “W...
Sarepta Therapeutics to Announce First Quarter 2024 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2024 financial results after the Nasd...
Outperforming ETF manager names a potential ‘50-bagger' in the stock market
The Simplify Health Care exchange-traded fund has grown to $136 million in assets in two and a half years. It is never easy for an actively managed fund to outperform its benchmark or a broad stock-ma...
Sarepta Therapeutics to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in fire...